Related Experiment Video

Updated: Jul 23, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Targeting molecular signals in chk1 pathways as a new approach for overcoming drug resistance

G Hapke1, M B Yin, Y M Rustum

  • 1Department of Pharmacology and Therapeutics, Grace Cancer Drug Center Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

Cancer Metastasis Reviews
|February 8, 2002
PubMed

Insights

Cancer cells can become resistant to chemotherapy, hindering treatment success. This review explores how cell cycle, DNA repair, and cell death mechanisms contribute to this crucial drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemotherapy faces a major clinical challenge due to cancer cell drug resistance.
  • Drug resistance arises from mechanisms like altered drug handling, reduced target interaction, and increasingly, cell cycle, DNA mismatch repair (MMR), and cell death pathways.
  • Understanding these resistance mechanisms is vital for improving cancer treatment efficacy.

Purpose of the Study:

  • To review the role of cell cycle progression, DNA mismatch repair (MMR), and p73 in regulating cancer cell resistance to anticancer drugs.
  • To examine the involvement of altered apoptotic cell death in resistance to DNA-damaging agents.

Main Methods:

  • Literature review of studies on cancer cell resistance mechanisms.
  • Analysis of pathways including Chk1 regulation, DNA MMR, p73, and apoptosis.
  • Focus on resistance to DNA-damaging chemotherapeutic agents.

Main Results:

  • Drug resistance is multifactorial, involving drug pharmacokinetics and pharmacodynamics.
  • Cell cycle checkpoints, DNA repair (MMR), and apoptosis regulation are key determinants of sensitivity or resistance.
  • Specific pathways like Chk1 and p73 play significant roles in mediating resistance.

Conclusions:

  • Cell cycle, DNA MMR, and apoptosis pathways are critical regulators of cancer cell resistance to chemotherapy.
  • Targeting these pathways presents potential strategies to overcome drug resistance and enhance treatment outcomes.
  • Further research into these molecular mechanisms is essential for developing more effective cancer therapies.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...